Bio-Techne (NASDAQ: TECH) reported Q2 EPS of $0.40, $0.01 worse than the analyst estimate of $0.41. Revenue for the quarter came in at $272.6 million versus the consensus estimate of $277.55 million.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.